CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 21 enrolled
Drug / intervention
Revefenacin Inhalation Solution [Yupelri] +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04315558
NCT04315558Phase 2Completed
CompareCT.gov

Revefenacin in Acute Respiratory Insufficiency in COPD (RARICO)

University of California, Los Angeles·interventional·Posted Mar 19, 2020·Updated Aug 13, 2025

In Brief

A Phase 2 clinical trial evaluating Revefenacin Inhalation Solution [Yupelri] and Ipratropium Bromide for COPD and Acute Respiratory Failure. Completed, enrolled 21 participants across 2 sites.

Detailed Summary

RARICO is a pragmatic, randomized, controlled, double-blinded, multi-center trial evaluating the safety and feasibility of nebulized revefenacin in comparison to nebulized ipratropium in patients with COPD and acute respiratory failure requiring invasive mechanical ventilation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOPD, Acute Respiratory Failure
CountriesUnited States
CollaboratorsTheravance Biopharma, Mylan Pharmaceuticals Inc

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedMar 19, 2020
Enrollment StartNov 1, 2020
Primary CompletionJan 1, 2025
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 6.3 years ago

Interventions

Revefenacin Inhalation Solution [Yupelri]drug

nebulized drug comparison

Ipratropium Bromidedrug

nebulized drug comparison